The U.S. Food and Drug Administration said on Wednesday it will hold a meeting of experts on May 22 to discuss COVID-19 ...

Analysts are estimating that Novavax will report an earnings per share (EPS) of $0.19. The market awaits Novavax's ...

Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference.

Officials in sixteen states and the District of Columbia sued in response, leading to Tuesday’s order from U.S. District ...

Novavax (NasdaqGS:NVAX) recently amended its collaboration agreement with Takeda, enhancing its revenue potential through a new upfront payment structure and future royalties. These developments, ...

Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.

Yes, according to leading vaccine physician Paul Offit, who denounced the new placebo-controlled trial requirements for ...

A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a study, but U.S. government regulators ...

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine is sowing uncertainty about other ...

We expect Novavax NVAX to surpass expectations when it reports first-quarter 2025 earnings on May 8, before the opening bell.

Shares of Novavax Inc. NVAX slipped 3.90% to $6.41 Thursday, on what proved to be an all-around great trading session for the ...

Novavax (NASDAQ:NVAX) has updated the terms of the previously announced collaboration and licensing agreement with Takeda (TAK).